WO2003068801A3 - Antibody variants with faster antigen association rates - Google Patents

Antibody variants with faster antigen association rates Download PDF

Info

Publication number
WO2003068801A3
WO2003068801A3 PCT/US2003/004184 US0304184W WO03068801A3 WO 2003068801 A3 WO2003068801 A3 WO 2003068801A3 US 0304184 W US0304184 W US 0304184W WO 03068801 A3 WO03068801 A3 WO 03068801A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody variants
association rates
antigen association
faster
faster antigen
Prior art date
Application number
PCT/US2003/004184
Other languages
French (fr)
Other versions
WO2003068801A2 (en
Inventor
Henry B Lowman
Jonathan S Marvin
Original Assignee
Genentech Inc
Henry B Lowman
Jonathan S Marvin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Henry B Lowman, Jonathan S Marvin filed Critical Genentech Inc
Priority to MXPA04007583A priority Critical patent/MXPA04007583A/en
Priority to BR0307548-6A priority patent/BR0307548A/en
Priority to KR10-2004-7012316A priority patent/KR20040082421A/en
Priority to CA002472922A priority patent/CA2472922A1/en
Priority to JP2003567927A priority patent/JP2006506943A/en
Priority to EP03739759A priority patent/EP1573002A4/en
Priority to AU2003216250A priority patent/AU2003216250A1/en
Publication of WO2003068801A2 publication Critical patent/WO2003068801A2/en
Publication of WO2003068801A3 publication Critical patent/WO2003068801A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds.
PCT/US2003/004184 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates WO2003068801A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA04007583A MXPA04007583A (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates.
BR0307548-6A BR0307548A (en) 2002-02-11 2003-02-11 Method of producing an antibody variant, antibody variant, composition, isolated nucleic acid, vector, host cell, process for producing an antibody variant, and method of determining the antigen association coefficient of an antibody
KR10-2004-7012316A KR20040082421A (en) 2002-02-11 2003-02-11 Antibody Variants with Faster Antigen Association Rates
CA002472922A CA2472922A1 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates
JP2003567927A JP2006506943A (en) 2002-02-11 2003-02-11 Antibody variants with high antigen binding rate
EP03739759A EP1573002A4 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates
AU2003216250A AU2003216250A1 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35589502P 2002-02-11 2002-02-11
US60/355,895 2002-02-11
US40968502P 2002-09-10 2002-09-10
US60/409,685 2002-09-10

Publications (2)

Publication Number Publication Date
WO2003068801A2 WO2003068801A2 (en) 2003-08-21
WO2003068801A3 true WO2003068801A3 (en) 2005-06-30

Family

ID=27737510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004184 WO2003068801A2 (en) 2002-02-11 2003-02-11 Antibody variants with faster antigen association rates

Country Status (9)

Country Link
US (4) US20030224397A1 (en)
EP (1) EP1573002A4 (en)
JP (1) JP2006506943A (en)
KR (1) KR20040082421A (en)
AU (1) AU2003216250A1 (en)
BR (1) BR0307548A (en)
CA (1) CA2472922A1 (en)
MX (1) MXPA04007583A (en)
WO (1) WO2003068801A2 (en)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2003087131A2 (en) * 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
JP5416338B2 (en) * 2003-05-09 2014-02-12 デューク ユニバーシティ CD20-specific antibody and method of use thereof
WO2004111233A1 (en) * 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
EP1639014B1 (en) * 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US20050227289A1 (en) * 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060018902A1 (en) * 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006033702A2 (en) * 2004-07-26 2006-03-30 Biogen Idec Ma Inc. Anti-cd154 antibodies
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
JP2008531060A (en) * 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド A method for humanizing immunoglobulin variable regions via rational modification of complementarity determining residues
US10011858B2 (en) * 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US20100261288A1 (en) 2005-06-13 2010-10-14 Fortebio, Inc. Tip tray assembly for optical sensors
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
CN105001320A (en) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US20070161042A1 (en) * 2006-01-11 2007-07-12 Fortebio, Inc. Methods for characterizing molecular interactions
WO2007108756A1 (en) * 2006-03-23 2007-09-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US11046784B2 (en) * 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2383297T5 (en) 2006-08-14 2022-07-04 Xencor Inc Optimized antibodies directed against CD19
US20100093106A1 (en) * 2006-09-14 2010-04-15 Fortebio, Inc. Amine-Reactive Biosensor
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
JP2010509369A (en) * 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド Methods for treating age-related macular degeneration
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (en) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer
TW201940502A (en) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 Variants derived from ActRIIB and uses therefor
TWI667038B (en) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 Pharmaceutical composition comprising an actriia-fc fusion protein; use of an actriia-fc fusion protein for treatment or prevention of cancer-related bone loss; use of an actriia-fc fusion protein for the treatment or prevention of multiple myeloma
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US9096651B2 (en) * 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
EP3415529B1 (en) * 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2742268T3 (en) 2007-12-26 2020-02-13 Xencor Inc Fc variants with altered FcRn binding
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
LT2708559T (en) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0912570B8 (en) * 2008-05-07 2021-05-25 Argos Therapeutics Inc humanized anti-ifn-alpha antibody, or an antigen-binding fragment thereof, therapeutic composition and its uses
RU2010153580A (en) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (en) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド Prostaglandin E2 double variable domain immunoglobulin and use thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT3750552T (en) 2008-08-14 2023-06-28 Acceleron Pharma Inc Gdf traps
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009308707A1 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
WO2010107110A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
TWI544077B (en) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
WO2010129532A2 (en) * 2009-05-05 2010-11-11 Trustees Of Boston University Method and device for rapid detection of bacterial antibiotic resistance/susceptibility
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
MX2011013364A (en) 2009-06-12 2012-03-16 Acceleron Pharma Inc Truncated actriib-fc fusion proteins.
KR20120034739A (en) 2009-06-17 2012-04-12 애보트 바이오테라퓨틱스 코포레이션 Anti-vegf antibodies and their uses
TW201119673A (en) 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
JP6267425B2 (en) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy
KR20120123299A (en) 2009-12-04 2012-11-08 제넨테크, 인크. Multispecific antibodies, antibody analogs, compositions, and methods
ES2594893T3 (en) * 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anti HER2 antibodies and their uses
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
FR2958753B1 (en) * 2010-04-13 2018-03-16 Institut De Recherche Pour Le Developpement (Ird) ANTIGENIC CONSTRUCTION AND ITS APPLICATIONS FOR THE DETECTION OF TRYPANOSOMOSES IN MAN AND ANIMALS
WO2011138462A1 (en) * 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP5682976B2 (en) * 2010-09-17 2015-03-11 国立大学法人東北大学 Method for determining the effectiveness of pharmaceuticals containing antibodies as components
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc Actriia binding agents and uses thereof
HUE038305T2 (en) 2010-11-17 2018-10-29 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
AU2012222252B2 (en) 2011-02-25 2016-08-25 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc antibody
WO2012133047A1 (en) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 Immunohistological staining method and method for determining effectiveness of antibody preparation using same
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013065708A1 (en) 2011-10-31 2013-05-10 中外製薬株式会社 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
BR112014015851A2 (en) 2011-12-30 2019-09-24 Abbvie Inc double specific binding proteins directed against il-13 and / or il-17
WO2014052713A2 (en) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Her2-and vegf-a-binding proteins with enhanced stability
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
KR102279522B1 (en) 2012-11-02 2021-07-19 셀진 코포레이션 Activin-actrii antagonists and uses for treating bone and other disorders
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CN105324396A (en) 2013-03-15 2016-02-10 艾伯维公司 Dual specific binding proteins directed against il-1 beta and il-17
PT3050896T (en) 2013-09-27 2021-08-24 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
WO2016090077A1 (en) 2014-12-03 2016-06-09 Celgene Corporation Activin-actrii antagonists and uses for treating anemia
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
KR102650420B1 (en) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
TW201735947A (en) 2016-03-14 2017-10-16 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN116271014A (en) 2016-08-05 2023-06-23 中外制药株式会社 Compositions for preventing or treating IL-8 related diseases
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TW202034958A (en) * 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632926B1 (en) * 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) * 1895-11-26 crosby
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL132239A0 (en) * 1997-04-07 2001-03-19 Genentech Inc Humanized antibodies and methods for forming humanized antibodies
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE419354T1 (en) * 2000-02-25 2009-01-15 Us Gov Health & Human Serv SCFV MOLECULES AGAINST EGFRVIII WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREOF, AND METHODS OF USE THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632926B1 (en) * 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FOGOLARI ET AL.: "Simulation of electrostatic effects in Fab-antigen complex formation", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 267, 2000, pages 4861 - 4869, XP002986093 *
MULLER ET AL.: "VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4.A resolution and mutational analysis of the interface", STRUCTURE, vol. 6, no. 9, 15 September 1998 (1998-09-15), pages 1153 - 1167, XP002986094 *
See also references of EP1573002A4 *
SELZER ET AL.: "Rational design of faster associating and tighter binding protein complexes", NATURE STRUCTURAL BIOLOGY, vol. 7, no. 7, July 2000 (2000-07-01), pages 537 - 541, XP008047548 *

Also Published As

Publication number Publication date
WO2003068801A2 (en) 2003-08-21
AU2003216250A1 (en) 2003-09-04
CA2472922A1 (en) 2003-08-21
US20080299115A1 (en) 2008-12-04
EP1573002A2 (en) 2005-09-14
KR20040082421A (en) 2004-09-24
US20070037255A1 (en) 2007-02-15
US20030224397A1 (en) 2003-12-04
MXPA04007583A (en) 2005-04-25
JP2006506943A (en) 2006-03-02
BR0307548A (en) 2006-01-17
EP1573002A4 (en) 2008-07-16
US20100291072A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2003068801A3 (en) Antibody variants with faster antigen association rates
HRP20151252T4 (en) Modified antibody fab fragments
IL172871A (en) Isolated human antibody or antigen-binding fragment thereof, an immunoconjugate, a single chain antibody molecule and a polypeptide comprising the same and uses thereof
HK1081647A1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
WO2006130458A3 (en) Antibodies directed to cd20 and uses thereof
IN2009KN02655A (en)
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2004108889A3 (en) Hybrid antibodies
WO2005016111A3 (en) Antibodies directed to parathyroid hormone (PTH) and uses thereof
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
AU2003265883A1 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2003048321A3 (en) Hybrid antibodies
WO2004050683A3 (en) Antibodies directed to tumor necrosis factor and uses thereof
WO2006081139A3 (en) Antibodies against interleukin-1 beta
WO2005068503A3 (en) M-csf-specific monoclonal antibody and uses thereof
IL176940A (en) Isolated antibody or an antigen binding fragment thereof that binds ige
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
EP1607404A4 (en) Monoclonal antibody and hybridoma producing the same
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
EP1491555A4 (en) Anti-human hepatoma monoclonal antibody hab18 light/heavy chain variable region gene, and use thereof
WO2005026210A3 (en) Therapeutic binding molecules
WO2005023201A3 (en) Methods for treating rheumatoid arthritis
AU2002359495A1 (en) Anti-tnf antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2472922

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004/05725

Country of ref document: ZA

Ref document number: 200405725

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 163109

Country of ref document: IL

Ref document number: 2003216250

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003739759

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 534280

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007583

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047012316

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003567927

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038081253

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003739759

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0307548

Country of ref document: BR